DL-Pyroglutamic acid
CAS No. 149-87-1
DL-Pyroglutamic acid( —— )
Catalog No. M28638 CAS No. 149-87-1
DL-Pyroglutamic acid exhibited a strong inactivating effect on hepatitis B surface antigen.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 49 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDL-Pyroglutamic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionDL-Pyroglutamic acid exhibited a strong inactivating effect on hepatitis B surface antigen.
-
DescriptionDL-Pyroglutamic acid exhibited a strong inactivating effect on hepatitis B surface antigen.
-
In VitroDL-Pyroglutamic acid results 50 and 100% inactivation of the antigen of 0.01-0.025% and 0.025-0.05%, respectively.DL-Pyroglutamic acid is a possible glutamate antagonist, blocks glutamate miniature-end-plate potential in locust muscle-Druce and Bradford.
-
In VivoDL-Pyroglutamic acid (0.775 mM/L) completely abolishes the myoclonic jerks and EEG spikes in rats model of epileptic by cobalt implantation in the sensorimotor cerebral cortex.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorPyroptosis|Caspase-1|IL-1β|inflammation
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number149-87-1
-
Formula Weight129.114
-
Molecular FormulaC5H7NO3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (774.53 mM)
-
SMILESO=C(O)C(CC1)NC1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Rabuffetti, M., Sciorati, C., Tarozzo, G., et al. Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. Journal of Neuroscience 20, 4398-4404 (2000).
molnova catalog
related products
-
[Ser25] - PKC (19 - ...
[Ser25] - PKC (19 - 36) Substrate
-
Caffeic acid 4-O-glu...
Caffeic acid 4-O-glucoside showed significant axonal elongation effects on Aβ25-35-induced atrophy.
-
Sergliflozin etabona...
Sergliflozin etabonate, a SGLT-2 inhibitor, is used potentially for the treatment of type 2 diabetes and obesity.
Cart
sales@molnova.com